Advisory Committee

Olalekan “Lekan” Ajayi, PharmD, MBA, FACCC, is Chief Operating Officer for Highlands Oncology Group, P.A. In this role, Dr. Ajayi oversees the deployment of strategic initiatives into operational goals for all organizational service lines, including oncology. Dr. Ajayi currently serves on the Association of Community Cancer Centers (ACCC) Board of Trustees as the secretary.

Dr. Ajayi is passionate about leadership development and building high-performance teams through the application of operational excellence principles. He holds a Doctor of Pharmacy from the University of Wyoming and a Master of Business Administration from the University of Colorado Denver.

Amy Ellis is the chief quality officer at Northwest Medical Specialties (NWMS), who oversees its quality improvement, strategic practice initiatives, and value-based care programs, including the Oncology Care Model, Oncology Medical Home, and various commercial payment models. Amy works to continually transform the way care is provided to patients by utilizing innovative tools, such as artificial intelligence, care management technology, electronic patient-reported outcomes, population health technology, continual process improvement, and data analysis.

Amy brings 15 years of healthcare experience to the NWMS team, which includes clinical oncology research and alternative payment model implementation. Amy has been recognized for her work on the Payment Reform Committee with the Community Oncology Alliance, her active involvement in the Association of Community Cancer Centers’ committees and practice initiatives, as well as her value-based care leadership with the Quality Cancer Care Alliance Network and Washington state oncology initiatives. Amy is passionate about the quality of care provided to patients and strives to improve outcomes and the patient experience.

In 2019, Amy received a HemOnc Today’s Next Gen Innovator award for her forward-thinking approach in cancer care.

Douglas Flora, MD, LSSBB, FACCC, serves as the executive medical director of Oncology Services at St. Elizabeth Cancer Center and was recently named the Robert and Dell Ann Sathe Endowed chair in Oncology. Dr. Flora is a board member of the Kentucky Society of Clinical Oncology, Andy & JJ Dalton Foundation, and American Cancer Society Area Board for Ohio, West Virginia, and Northern Kentucky.

He was born and raised in Cincinnati, Ohio, graduating from The Ohio State University College of Medicine in 1999. Dr. Flora has been named a Cincinnati Magazine “Top Doctor” in hematology and oncology for the past 15 years.

Dr. Doug Flora is the Executive Medical Director of Oncology Services and The Robert and Dell Ann Sathe Endowed Chair in Oncology at the Yung Family Cancer Center at St. Elizabeth Healthcare. Headquartered in Edgewood, Kentucky, St. Elizabeth Healthcare currently operates six facilities throughout Northern Kentucky and Southeastern Indiana. 

Dr. Flora graduated from The Ohio State University College of Medicine in 1999. With a distinguished career spanning over two decades, he is a steadfast advocate for whole-person care and medical innovation.  His leadership and vision have led to cutting-edge technology and treatment protocols and improved patient outcomes. 

As the Editor-In-Chief for the pioneering peer-reviewed research journal AI in Precision Oncology, Dr. Flora plays a pivotal role in medical education and research, nurturing the next generation of healthcare leaders. His unique perspective is enriched by personal experience as a practicing oncologist, senior healthcare executive, and, most importantly, a cancer survivor. These roles provide distinctive insights into the complexities and challenges faced in oncology care from different angles and drive home the reality that AI tools will allow optimization of every aspect of cancer care, none more urgently than what the patients personally require and deserve. 

Dr. Flora is President-Elect of the Association of Cancer Care Centers, is a Board Member of the American Cancer Society, and is a Board Member of the Kentucky Society of Clinical Oncology. He enjoys international travel with his family in his spare time. 

Sarah Hudson-DiSalle oversees the medication assistance program and reimbursement services for infusion services at The Ohio State University Comprehensive Cancer Center – The James. She has extensive experience in healthcare information technology, hospitals, managed care, pharmaceutical revenue cycle management, patient access to pharmaceuticals, and healthcare management.

Dr. Hudson-DiSalle earned her Bachelor of Science in Pharmacy from the University of Toledo and, after practicing pharmacy for seven years, completed her Doctor of Pharmacy at The Ohio State University. She is dedicated to improving patient access and reimbursement services for infusion medications at The James Cancer Hospital.

Dr. Edward Kim serves as Physician-in-Chief of City of Hope Orange County and Vice Physician-in-Chief of City of Hope National Medical Center. His vision focuses on strategic, team-oriented translational research and patient advocacy to increase accessibility and equity in cancer care.

Recognized as a U.S. News & World Report "Top Doctor," Dr. Kim is renowned for his oncology expertise and is positioned to drive innovation in cancer care delivery. He is developing new paradigms for translating research into clinical practice and introducing therapies throughout the Orange County clinical network.

Backed by a distinguished history of pioneering cancer research, Dr. Kim is among the country's foremost experts in molecular prognostication―which advances cancer detection and personalized therapies―for lung, head, and neck cancers. He has served as principal/co-principal investigator on numerous studies and protocols and authored over 200 publications in journals including The Lancet, Journal of Clinical Oncology, and Cancer Discovery.

Before joining City of Hope, Dr. Kim chaired Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute and held the Donald S. Kim Distinguished Chair for Cancer Research. He recently completed his MBA at University of North Carolina Kenan-Flagler Business School.

Nikoletta Sidiropoulos, MD, is an associate professor of Pathology and Laboratory Medicine at the University of Vermont (UVM) Larner College of Medicine, and she is the inaugural medical director of the Genomic Medicine Program at the UVM Medical Center. Dr. Sidiropoulos’ areas of expertise include molecular genetic pathology with subspecialty interests in oncology and quality improvement.

Dr. Sidiropoulos is a diplomate of the American Board of Pathology and American Board of Preventive Medicine in clinical informatics. She is also a member of the Roundtable on Genomics and Precision Health at The National Academies of Sciences, Engineering, and Medicine, and she is professionally involved with both the College of American Pathologists and Association for Molecular Pathology.

Dr. Sidiropoulos received her medical degree from the University of Connecticut School of Medicine, graduating with the award in “Excellence in Medical Studies.” She completed her residency in anatomic and clinical pathology at Dartmouth Hitchcock Medical Center and subsequently completed fellowships in cytopathology and molecular genetic pathology.